Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.


Related Content

On Building A Better R&D Machine, Part 1: Pfizer’s R&D Chief Mikael Dolsten Talks Organizational Structure And Innovation
Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity
Inserting Prevnar 13 Into Adult Treatment Guidelines Could Raise Questions For Practitioners
Prevnar 13 In Older Adults Appears To Have Smooth Path To FDA Approval
Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts